Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Buy” by Brokerages

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have received a consensus recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $49.50.

A number of research analysts recently weighed in on PCRX shares. JPMorgan Chase & Co. assumed coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an “overweight” rating and a $45.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Monday, March 4th. TheStreet upgraded shares of Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Wedbush restated an “outperform” rating and set a $57.00 price objective on shares of Pacira BioSciences in a research note on Thursday, February 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $45.00 target price on shares of Pacira BioSciences in a research note on Tuesday, April 9th.

Insider Activity

In related news, Director Gary W. Pace sold 90,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now owns 22,127 shares in the company, valued at $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary W. Pace sold 90,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now owns 22,127 shares of the company’s stock, valued at $677,086.20. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Legato Capital Management LLC bought a new position in Pacira BioSciences in the 3rd quarter worth $295,000. SG Americas Securities LLC raised its stake in shares of Pacira BioSciences by 37.7% in the third quarter. SG Americas Securities LLC now owns 21,843 shares of the company’s stock worth $670,000 after buying an additional 5,979 shares during the period. Everence Capital Management Inc. lifted its position in shares of Pacira BioSciences by 46.3% during the 3rd quarter. Everence Capital Management Inc. now owns 8,940 shares of the company’s stock valued at $274,000 after buying an additional 2,830 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Pacira BioSciences during the 3rd quarter valued at approximately $466,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Pacira BioSciences by 33.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,946 shares of the company’s stock worth $336,000 after acquiring an additional 2,764 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 2.7 %

NASDAQ:PCRX opened at $26.81 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.24 and a quick ratio of 4.17. The firm’s 50-day moving average price is $28.91 and its 200-day moving average price is $29.73. The company has a market capitalization of $1.25 billion, a PE ratio of 33.10 and a beta of 0.76. Pacira BioSciences has a 1-year low of $25.74 and a 1-year high of $48.60.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The business had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million. On average, equities analysts predict that Pacira BioSciences will post 2.18 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.